knowledge -WSS

knowledge

author：entertainment 2025-10-01 22:17:15 - browse：8253

A sign of Lilly on the top of its biotechnology center — coverage from STAT — Adobe

Eli Lilly reported Thursday that its experimental weekly insulin worked as well as daily basal insulin products in two late-stage studies, paving the way for the drug to compete with a similar weekly insulin developed by Novo Nordisk.

In a 52-week trial of type 2 diabetes patients using insulin for the first time, those on the weekly insulin, called efsitora alfa, had a 1.34% reduction in blood sugar levels, while people on the comparator daily insulin degludec, sold as Tresiba by Novo, had a 1.26% lowering. That resulted in patients having blood sugar levels, known as A1C readings, of 6.87% and 6.95%, respectively.

In a separate 26-week trial of type 2 patients who have been using insulin, those on efsitora and the comparator daily insulin glargine, sold by Lilly as Basaglar and Sanofi as Lantus, both saw A1C reductions of 1.07%, resulting in blood sugar levels of 7.12% and 7.11%, respectively.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Novo Nordisk touts Wegovy study, but still struggling with supply

WSS

Ohio still needs to do more to protect the right to abortion

What is STAT's opinion section for?

Biogen’s boardroom scandal saddles CEO with first crisis

Aspartame and sugar

Indictment alleges Trump's ex

CVS, Rite Aid closures threaten to worsen pharmacy deserts

focus

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Moonlake's readout produced a cash windfall. Risks remain

Readout Newsletter: Ozempic panic wanes, Legend x Novartis, etc.

Apple is now the first public company to be valued at $3 trillion

UnitedHealth sued over use of algorithm in Medicare Advantage plans

The high cost of giving birth even with insurance

Surge in Apellis stock fueled by confidence in safety of its eye drug

DIEP, the 'gold standard' of breast reconstruction, is under threat

Maui wildfire now ranks as the fifth

ChatGPT in medicine: STAT answers readers' burning questions

YouTube cracks down on misinformation on cancer treatment

entertainment

Readout LOUD Podcast: Lilly's obesity drug, the power of radiation

Study suggests Covid rebound is far more common with Paxlovid than without

Senators push IRS to launch nonprofit hospital probe

Biogen’s boardroom scandal saddles CEO with first crisis

After decades in use, heart stents finally beat placebo

Surge in Apellis stock fueled by confidence in safety of its eye drug

focus

hotspot

focus

hotspot